Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at Hard-to-Treat autoimmune diseases

NCT ID NCT06939166

First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 21 times

Summary

This early-phase study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, in up to 12 adults with severe autoimmune diseases affecting the brain and nerves, such as multiple sclerosis and myasthenia gravis. The main goal is to check if the treatment is safe and to find the right dose. These cells are made from a healthy donor, so they are ready to use without needing to collect the patient's own cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Huanhu Hospital

    RECRUITING

    Tianjin, China

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.